Industry
Biotechnology
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Loading...
Open
3.01
Mkt cap
317M
Volume
1.2M
High
3.29
P/E Ratio
-2.57
52-wk high
13.01
Low
2.95
Div yield
N/A
52-wk low
2.70
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
October 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
September 10, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:04 am
Portfolio Pulse from Benzinga Insights
August 08, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 1:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:26 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.